Search results
· Experience: Stemline Therapeutics · Location: United States · 500+ connections on LinkedIn. View Kevin P. Carlin’s profile on LinkedIn, a professional community of 1 billion members.
Kevin P. is currently serving as the Vice President of Sales for Solid Tumors at Stemline Therapeutics since January 2023. Prior to that, they held the position of Vice President of Sales for the US Oncology Business Unit at Takeda from October 2019 to January 2023.
I’m happy to share that I’m starting a new position as Vice President of Sales - Solid Tumors at Stemline Therapeutics! | 128 comments on LinkedIn
10 cze 2020 · Menarini acquired Stemline for an upfront payment of $11.50 per share in cash and one non-tradeable Contingent Value Right (CVR) that will entitle each holder to an additional $1.00 per share in cash upon completion of the first sale of ELZONRIS in any EU5 country after European Commission approval.
At Stemline, we are committed to applying our scientific leadership to transform the lives of people with cancer. We are focused on the development of a broad pipeline of innovative, transformative therapies in oncology.
21 mar 2024 · View Kevin Carlin's email address (k*****@stemli***.com) and phone number. Kevin works at Stemline Therapeutics, Inc. as Vice President of Sales - Solid Tumors. Kevin is based out of United States and works in the Biotechnology Research industry.
Stemline commercializes Elzonris®, a novel targeted treatment directed to CD123 for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare hematologic cancer, in the United States and Europe, the only approved treatment for BPDCN in the US and EU to date.
